The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tkacheva O.N.

Pirogov Russian National Research Medical University — Russian Clinical and Research Center of Gerontology

Mkhitaryan E.A.

Pirogov Russian National Research Medical University — Russian Clinical and Research Center of Gerontology

Cherdak M.A.

Pirogov Russian National Research Medical University — Russian Clinical and Research Center of Gerontology

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education;
Sechenov First Moscow State Medical University (Sechenov University)

Zhitkova Yu.V.

Interregional Clinical Diagnostic Center

Lobzin V.Yu.

Kirov Military Medical Academy;
North-Western State Medical University

Kurushina O.V.

Volgograd State Medical University

Vasenina E.E.

Russian Medical Academy of Continuing Professional Education

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

The patient pathway in the diagnosis and treatment of mild cognitive impairment and new therapeutic opportunities. Resolution of the Expert Council (Moscow, April 21, 2025)

Authors:

Tkacheva O.N., Mkhitaryan E.A., Cherdak M.A., Bogolepova A.N., Ostroumova O.D., Zhitkova Yu.V., Lobzin V.Yu., Kurushina O.V., Vasenina E.E., Zaharov V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(11): 100‑104

DOI: 10.17116/jnevro2025125111100

Read: 871 times

Buy for 300₽
Contact the author
Table of contents

THE PATIENT PATHWAY IN THE DIAGNOSIS AND TREATMENT OF MILD COGNITIVE IMPAIRMENT AND NEW THERAPEUTIC OPPORTUNITIES. RESOLUTION OF THE EXPERT COUNCIL (MOSCOW, APRIL 21, 2025)
THE PATIENT PATHWAY IN THE DIAGNOSIS AND TREATMENT OF MILD COGNITIVE IMPAIRMENT AND NEW THERAPEUTIC OPPORTUNITIES. RESOLUTION OF THE EXPERT COUNCIL (MOSCOW, APRIL 21, 2025)

To cite this article:

Tkacheva ON, Mkhitaryan EA, Cherdak MA, et al. The patient pathway in the diagnosis and treatment of mild cognitive impairment and new therapeutic opportunities. Resolution of the Expert Council (Moscow, April 21, 2025). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(11):100‑104. (In Russ.)
https://doi.org/10.17116/jnevro2025125111100

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
Change of subjective cognitive decline in first-degree rela­tives of patients with Alzheimer’s disease: resu­lts of a 15-year prospective study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):36-42
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Stru­ctural features of the brain in amne­stic mild cognitive impairment and their correlation with mild beha­vioral impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):112-119
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Angiotensin model as a new approach to study of mese­nchymal stem cell sene­scence. Russian Cardiology Bulletin. 2025;(2):20-26
Asso­ciations between sali­vary mela­tonin and periodontal disease: a systematic review and meta-analysis. Stomatology. 2025;(3):87-96
Abstract:

The Expert Council «The Patient Pathway in the Diagnosis and Treatment of Mild Cognitive Impairment (MCI) and New Therapeutic Opportunities» was held in Moscow on April 21, 2025. The purpose of the council was to discuss the challenges related to identifying patients with MCI and the long pathway to diagnosis. Experts discussed the diagnosis of MCI as well as new therapeutic opportunities for slowing the progression of dementia. The meeting was opened by Corresponding Member of the Russian Academy of Sciences, Prof. O.N. Tkacheva, who emphasized the burden of MCI in the Russian Federation (RF) and worldwide. Then, PhD E.A. Mkhitaryan and PhD M.A. Cherdak addressed the issue of MCI underdiagnosis at various stages of medical care. Prof. O.V. Kurushina and DSc Yu.V. Zhitkova presented data on cognitive impairment (CI) in specific regions of Russia. Prof. V.Yu. Lobzin provided data on the role of sleep disturbances in the development of CI, and Prof. A.N. Bogolepova discussed the use of the combination of melatonin 3 mg+memantine 5 mg, registered in the RF for the treatment of mild and moderate CI. Continuing the discussion on the place of this combination in clinical practice, Prof. O.D. Ostroumova presented patient profiles for whom this therapy is indicated. Prof. E.E. Vasenina outlined various approaches to the prevention and treatment of MCI. Prof. V.V. Zakharov discussed aspects of MCI pathogenesis. During the council, a discussion was held on defining clinical phenotypes of MCI patients and positioning the combination of melatonin 3 mg+memantine 5 mg (Miladean) considering its mechanism of action. As a result of the discussion, it was proposed to consider Miladean as part of pharmacological correction for pre-dementia cognitive impairment. Following the session, the moderators presented the participants with a draft resolution, which was revised according to comments and suggestions received. The final version of the resolution, published below, was approved by all members of the council.

Keywords:

mild cognitive impairment
neuroinflammation
Miladean
memantine
melatonin

Authors:

Tkacheva O.N.

Pirogov Russian National Research Medical University — Russian Clinical and Research Center of Gerontology

Mkhitaryan E.A.

Pirogov Russian National Research Medical University — Russian Clinical and Research Center of Gerontology

Cherdak M.A.

Pirogov Russian National Research Medical University — Russian Clinical and Research Center of Gerontology

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education;
Sechenov First Moscow State Medical University (Sechenov University)

Zhitkova Yu.V.

Interregional Clinical Diagnostic Center

Lobzin V.Yu.

Kirov Military Medical Academy;
North-Western State Medical University

Kurushina O.V.

Volgograd State Medical University

Vasenina E.E.

Russian Medical Academy of Continuing Professional Education

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

Received:

23.10.2025

Accepted:

27.10.2025

Close metadata

References:

  1. Tifratene K, Robert P, Metelkina A, et al. Progression of mild cognitive impairment to dementia due to AD in clinical settings. Neurology. 2015;85(4):331-338.  https://doi.org/10.1212/WNL.0000000000001788
  2. McGrattan AM, Pakpahan E, Siervo M, et al. Risk of conversion from mild cognitive impairment to dementia in low- and middle-income countries: a systematic review and meta-analysis. Alzheimers Dement (Transl Res Clin Interv). 2022;8(1):e12267. https://doi.org/10.1002/trc2.12267
  3. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252-265.  https://doi.org/10.1111/j.1600-0447.2008.01326.x
  4. Gao S, Unverzagt FW, Hall KS, et al. Mild cognitive impairment, incidence, progression, and reversion: findings from a community-based cohort of elderly African Americans. Am J Geriatr Psychiatry. 2014;22(7):670-681.  https://doi.org/10.1016/j.jagp.2013.02.015
  5. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.  https://doi.org/10.1016/S0140-6736(20)30367-6
  6. Yakhno NN, Tkacheva ON, Gavrilova SI, et al. Comprehensive interdisciplinary and interdepartmental program for prevention, early detection, diagnosis, and treatment of cognitive disorders in elderly and senile people. Russian Journal of Geriatric Medicine. 2022;(1):6-16. (In Russ.). https://doi.org/10.37586/2686-8636-1-2022-6-16
  7. Drapkina OM, Boytsov SA, Atyunina IV, et al. Dispensary observation of patients with arterial hypertension by a general practitioner in primary health care. Primary Health Care. 2025;2(2):20-39. (In Russ.). https://doi.org/10.15829/3034-4123-2025-55
  8. Isaev RI, Mkhitaryan EA, Cherdak MA, et al. The role of sleep in aging processes. Problems of Geroscience. 2024;(3):141-153. (In Russ.). https://doi.org/10.37586/2949-4745-3-2024-141-153
  9. Levin OS, Zakharov VV, Khacheva KK, et al. Pathogenetic therapy of cognitive impairment: results of a multicenter placebo-controlled clinical trial of the efficacy and safety of Miladean. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(10):60-68. (In Russ.). https://doi.org/10.17116/jnevro202312310160
  10. Tkacheva ON, Yakhno NN, Neznanov NG, et al. Clinical guidelines «Cognitive disorders in the elderly and senile persons». S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(3-3):7-149. (In Russ.). https://doi.org/10.17116/jnevro2025125337
  11. Ostroumova OD, Parfenov VA, Ostroumova TM, et al. Expert consensus: the effect of antihypertensive therapy on cognitive functions. Systemic Hypertension. 2021;18(1):5-12. (In Russ.). https://doi.org/10.26442/2075082X.2021.1.200575
  12. Bogolepova AN, Illarioshkin SN, Poluektov MG, et al. Mechanisms of cognitive disorders development and possibilities of their pharmacological correction using Miladean from pre-dementia to dementia stage. Nervnye Bolezni (Nervous Diseases). 2023;(4):18-28. (In Russ.). https://doi.org/10.24412/2226-0757-2023-13042
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.